Novo Nordisk sues Teva over generic drug development
Novo Nordisk has landed in legal dispute with Israeli pharmaceutical company Teva, as the latter company is intending to launch a generic version of Novo Nordisk’s obesity treatment Saxenda.
by marketwire translated by daniel pedersen
According to a filing on the US court database, Novo Nordisk is bringing legal action against Israeli pharmaceutical company Teva, as reported by Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck preps for war against generic drugmakers in US
For subscribers
.jpg)
.jpg&w=384&q=75)
